Abbott
30,025.00
-180.00(-0.60%)
Market Cap₹63,801.03 Cr
PE Ratio41.61
IndustryHealthcare
Company Performance:
1D-0.60%
1M+0.86%
6M-0.65%
1Y+9.17%
5Y+95.55%
View Company Insightsright
More news about Abbott
25Sept 25
ABB India Shares Slump 35% in 12 Months Amid Operational Challenges
ABB India's stock has declined over 35% in the past year, underperforming peers like Siemens and Cummins India. The company faces operational challenges including sluggish decision-making, soft large-ticket business, margin pressures, and revenue shortfalls. Current P/E ratio is 57, a 23% discount to its 5-year average. Despite challenges, some analysts maintain cautious optimism, citing potential for faster order conversion and stronger project pipeline. Market sentiment suggests range-bound growth in the near term.
11Sept 25
Abbott India Seeks Shareholder Approval for Darshan Gada's Director Appointment
Abbott India Limited has initiated a postal ballot to appoint Darshan Gada as a Non-Executive Director. Gada, a 43-year-old Chartered Accountant with 21 years of finance experience, currently serves as Regional Finance Director at Abbott Healthcare Private Limited. The e-voting period is from September 15 to October 14, 2025, with results to be declared by October 16, 2025. Shareholders can access the Postal Ballot Notice on the company's website and KFin Technologies' e-voting platform.
29Aug 25
ABB India Secures ₹174 Crore Wind Turbine Converter Order, Reports Mixed Q3 Results
ABB India has won a ₹173.55 crore order from Siemens Gamesa for wind turbine converters and electrical cabinets, to be delivered from January to December 2026. The company's Q3 financial results show a 12.20% increase in revenue to ₹3,175.40 crore, but a 20.50% decrease in net profit to ₹351.70 crore. EBITDA also declined by 27.00% to ₹441.00 crore. Managing Director Sanjeev Sharma attributed the profit decline to forex volatility and one-time factors. Despite mixed results, ABB India's shares traded 0.76% higher at ₹5,039.00 following the order announcement.
26Aug 25
Abbott India Unveils FreeStyle Libre 2 Plus: Advanced Glucose Monitoring Device
Abbott India has introduced the FreeStyle Libre 2 Plus, a next-generation continuous glucose monitoring device for diabetes management. The device offers minute-by-minute glucose readings and customizable alarms for glucose levels outside the target range. This innovation aims to provide users with more precise data for better diabetes management decisions. Pricing and availability details have not been disclosed.
14Aug 25
Abbott India Shareholders Approve All Resolutions at 81st Annual General Meeting
Abbott India Limited held its 81st Annual General Meeting on August 13, 2025, via video conferencing. Shareholders approved all proposed resolutions, including the adoption of financial statements, declaration of a final dividend, reappointment of directors, appointment of secretarial auditors, ratification of cost auditor remuneration, and appointment of Mr. Kartik Rajendran as Director and Managing Director for five years. The voting process, conducted through NSDL, saw overwhelming support for all resolutions, with most receiving over 99% votes in favor. The company promptly submitted voting results and the scrutinizer's report to BSE Limited, demonstrating commitment to transparency and good corporate governance.
12Aug 25
Abbott India Reports Robust Q1 Performance with 11% Revenue Growth
Abbott India Limited announced robust Q1 FY2025 financial results. Revenue increased by 11.6% to ₹1,738.35 crore, while net profit grew 11.5% to ₹365.86 crore. EBITDA rose 14.1% to ₹445 crore, with the EBITDA margin improving to 25.63%. The company also appointed Mr. Darshan Gada as an Additional (Non-Executive) Director, effective August 18, 2025, subject to shareholder approval.
05Aug 25
ABB India Faces Industrial Project Slowdown, Targets 12-15% Profit Margin for 2025
ABB India reported a record order backlog exceeding Rs 10,000 crore, with 90% of business from the domestic market. The company is experiencing cyclical challenges in its systems order segment due to customer delays. Q2 results showed a 20.7% decrease in net profit to Rs 351.70 crore, while revenue grew 12.2% to Rs 3,175.40 crore. EBITDA margin fell to 13% from 19.2%. Despite challenges, ABB India sees strong demand in tier-1, tier-2, and tier-3 markets, particularly in infrastructure, real estate, and data centers. The company aims for 12-15% profit margins by 2025.
04Aug 25
ABB India Q2 Results: Revenue Grows 12% Amid Margin Pressure
ABB India's Q2 results show a 12% revenue growth to ₹3,175.00 crore, meeting expectations. However, profitability declined with EBITDA falling 24% to ₹414.90 crore and net profit decreasing by 21% year-on-year. EBITDA margin dropped to 13% from 19.2%. The company faced significant cost increases across various categories, including a 26% rise in raw material costs. Order inflow declined by 12% to ₹3,036.00 crore, but the order book grew 6% annually, crossing ₹10,000.00 crore. The board approved evaluating the potential incorporation of the Robotics division into a wholly-owned subsidiary. ABB India's stock closed 2.3% lower at ₹5,384.00 following the results.
02Aug 25
ABB India Q2 Profit Drops 21%, Revenue Grows Amid Margin Pressure
ABB India's Q2 financial results show a 12.2% year-over-year revenue increase to Rs 3,175.00 crore, beating estimates. However, net profit fell 21% to Rs 352.00 crore, missing analyst expectations. EBITDA decreased 23.7% to Rs 414.00 crore, with margins contracting from 19.2% to 13.00%. The company declared an interim dividend of Rs 9.77 per share. Despite challenges, 18 out of 31 analysts maintain a 'Buy' rating on the stock.
01Aug 25
Abbott India Pays Rs. 2 Lakh Penalty to RBI for Exceeding Foreign Investment Limits
Abbott India Limited has been penalized Rs. 2 lakh by the Reserve Bank of India for violating foreign exchange laws. The violation occurred when foreign investment in the company exceeded 75% without prior government approval. The RBI issued a Compounding Order on July 31, 2025, concluding the compounding process. Abbott India will deposit the penalty amount and can now receive foreign institutional investments up to the prescribed limit.
16May 25
Abbott India's Q4 Profit Surges, Beats Estimates
Abbott India Ltd reported strong Q4 financial results, surpassing market expectations. Net profit increased by 14.7% to ₹359.00 crore, revenue rose by 9% to ₹1,633.00 crore, and EBITDA grew by 15% to ₹439.00 crore. The company's stock gained nearly 4% following the announcement, reaching ₹31,500.00 per share.
15May 25
Abbott India: Q4 Profit Soars 28%, ₹475 Dividend Proposed
Abbott India's Q4 results show strong growth with net profit up 27.90% to ₹367.00 crore, revenue increasing 11.50% to ₹1,604.60 crore, and EBITDA rising 30.00% with margin expansion to 26.70%. The company has recommended a final dividend of ₹475.00 per share, subject to shareholder approval.
Abbott
30,025.00
-180.00
(-0.60%)
1 Year Returns:+9.17%
Industry Peers
Sun Pharmaceutical
1,804.90
(+1.58%)
Divis Laboratories
6,510.00
(+1.53%)
Torrent Pharmaceuticals
3,755.80
(+0.28%)
Cipla
1,523.80
(+1.08%)
Dr Reddys Laboratories
1,248.00
(+0.96%)
Zydus Life Science
940.55
(+1.30%)
Lupin
2,071.60
(+1.43%)
Mankind Pharma
2,258.90
(+0.76%)
Aurobindo Pharma
1,227.40
(+1.61%)
Alkem Laboratories
5,773.00
(+1.26%)